Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia

References

• Abou Dalle I, Jabbour E, Short NJ. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. Ther Adv Hematol. 2020;11:204062072091002. doi:10.1177/2040620720910023
   Web of Science ®Google Scholar
• Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153–4162. doi:10.1182/blood-2008-11-185132
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9):1868–1876. doi:10.1182/blood-2011-09-377713
   PubMed Web of Science ®Google Scholar
• Jacquy C, Delepaut B, Van Daele S, et al. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse. Br J Haematol. 1997;98(1):140–146. doi:10.1046/j.1365-2141.1997.1792996.x
   PubMed Web of Science ®Google Scholar
• Cazzaniga G, Biondi A. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica. 2005;90(3):382–390.
   PubMed Web of Science ®Google Scholar
• Chen X, Wood BL. How do we measure MRD in ALL and how should measurements affect decisions. Re: treatment and prognosis? Best Pract Res Clin Haematol. 2017;30(3):237–248. doi:10.1016/j.beha.2017.07.002
   PubMed Web of Science ®Google Scholar
• Wood B. 9-Color and 10-color flow cytometry in the clinical laboratory. In: Archives of Pathology and Laboratory Medicine. Vol. 130. Allen Press;2006:680–690. doi:10.5858/2006-130-680-cacfci
   Google Scholar
• Tembhare PR, Ghogale S. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-106 and Is Superior to Standard Minimal Residual Disease Assay: a Study of 622 Patients. Cytom Part B Clin Cytom. 2020;98(1):57–67. doi:10.1002/CYTO.B.21831
   PubMed Web of Science ®Google Scholar
• Theunissen P, Mejstrikova E, Sedek L. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2017;129(3):347–357. doi:10.1182/BLOOD-2016-07-726307
   PubMed Web of Science ®Google Scholar
• Wood BL. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytom Part B - Clin Cytom. 2016;90(1):47–53. doi:10.1002/cyto.b.21239
   PubMed Web of Science ®Google Scholar
• Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275–1291. doi:10.1182/blood-2017-09-801498
   PubMed Web of Science ®Google Scholar
• van der Velden VHJ, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leuk. 2007;21(4):604–611. doi:10.1038/sj.leu.2404586
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Cazzaniga G, van der Velden VHJ, et al. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leuk. 2019;33(8):1910–1922. doi:10.1038/s41375-019-0413-0
   PubMed Web of Science ®Google Scholar
• Thörn I, Forestier E, Botling J, et al. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. Br J Haematol. 2011;152(6):743–753. doi:10.1111/j.1365-2141.2010.08456.x
   PubMed Web of Science ®Google Scholar
• Ryan J, Quinn F, Meunier A, et al. Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. Br J Haematol. 2009;144(1):107–115. doi:10.1111/j.1365-2141.2008.07429.x
   PubMed Web of Science ®Google Scholar
• Gaipa G, Cazzaniga G, Valsecchi MG, et al. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica. 2012;97(10):1586–1593. doi:10.3324/HAEMATOL.2011.060426
   Web of Science ®Google Scholar
• Van Dongen JJM, Van Der Velden VHJ, Brüggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125(26):3996–4009. doi:10.1182/blood-2015-03-580027
   PubMed Web of Science ®Google Scholar
• Wu D, Sherwood A, Fromm JR, et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med. 2012;4:134. doi:10.1126/scitranslmed.3003656
   Web of Science ®Google Scholar
• Pfeifer H, Cazzaniga G, van der Velden VHJ, et al. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia. 2019;33(8):1910–1922. doi:10.1038/s41375-019-0413-0
   PubMed Web of Science ®Google Scholar
• Theunissen PMJ, Van Zessen D, Stubbs AP, et al. Antigen receptor sequencing of paired bone marrow samples shows homogeneous distribution of acute lymphoblastic leukemia subclones. Haematologica. 2017;102(11):1869–1877. doi:10.3324/haematol.2017.171454
   PubMed Web of Science ®Google Scholar
• Theunissen PMJ, de Bie M, van Zessen D, de Haas V, Stubbs AP. van der Velden VHJ. Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: clonal evolution and implications for minimal residual disease target selection. Leuk Res. 2019;76:98–104. doi:10.1016/j.leukres.2018.10.009
   PubMed Web of Science ®Google Scholar
• Faham M, Zheng J, Moorhead M, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173–5180. doi:10.1182/blood-2012-07-444042
   PubMed Web of Science ®Google Scholar
• Monter A, Nomdedéu JF. ClonoSEQ assay for the detection of lymphoid malignancies. Expert Rev Mol Diagn. 2019;19(7):571–578. doi:10.1080/14737159.2019.1627877
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Morgades M, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA. J Clin Oncol. 2014;32(15):1595–1604. doi:10.1200/JCO.2013.52.2425
   PubMed Web of Science ®Google Scholar
• Brüggemann M, Raff T, Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood. 2012;120(23):4470–4481. doi:10.1182/blood-2012-06-379040
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Krawczyk-Kulis M, Giebel S, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD study. Br J Haematol. 2008;142(2):227–237. doi:10.1111/j.1365-2141.2008.07185.x
   PubMed Web of Science ®Google Scholar
• Brüggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107(3):1116–1123. doi:10.1182/blood-2005-07-2708
   PubMed Web of Science ®Google Scholar
• Beldjord K, Chevret S, Asnafi V, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123(24):3739–3749. doi:10.1182/blood-2014-01-547695
   PubMed Web of Science ®Google Scholar
• Mortuza FY, Papaioannou M, Moreira IM, et al. Minimal Residual Disease Tests Provide an Independent Predictor of Clinical Outcome in Adult Acute Lymphoblastic Leukemia. J Clin Oncol. 2002;20(4):1094–1104. doi:10.1200/jco.2002.20.4.1094
   PubMed Web of Science ®Google Scholar
• Vidriales MB, Pérez JJ, López-Berges MC, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood. 2003;101(12):4695–4700. doi:10.1182/blood-2002-08-2613
   PubMed Web of Science ®Google Scholar
• Ravandi F, Jorgensen JL, O’Brien SM, et al. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016;172(3):392–400. doi:10.1111/bjh.13834
   PubMed Web of Science ®Google Scholar
• Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580–e170580. doi:10.1001/jamaoncol.2017.0580
   PubMed Web of Science ®Google Scholar
• Bassan R, Brüggemann M, Radcliffe HS, Hartfield E, Kreuzbauer G, Wetten S. A systematic literature review and metaanalysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica. 2019;104(10):2028–2039. doi:10.3324/haematol.2018.201053
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Dombret H, Giebel S, et al. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematol. 2019;24(1):337–348. doi:10.1080/16078454.2019.1567654
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Kantarjian H, Wang X, et al. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020;95(2):144–150. doi:10.1002/ajh.25671
   PubMed Web of Science ®Google Scholar
• Issa GC, Kantarjian HM, Yin CC, et al. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017;123(3):459–467. doi:10.1002/cncr.30376
   PubMed Web of Science ®Google Scholar
• O’Connor D, Enshaei A, Bartram J, et al. Genotype-Specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2018;36(1):34–43. doi:10.1200/JCO.2017.74.0449
   PubMed Web of Science ®Google Scholar
• Xue Y, Cheng Y, Lu A, et al. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era. Biol Blood Marrow Transplant. 2019;25(8):1611–1620. doi:10.1016/j.bbmt.2018.12.007
   PubMed Web of Science ®Google Scholar
• Wang L, Du J, Huang A, et al. Chemotherapy vs. allogeneic transplantation as post molecular remission therapy in patients aged less than 60 years with Philadelphia-positive ALL. Bone Marrow Transplant. 2020;55(1):245–248. doi:10.1038/s41409-019-0514-4
   PubMed Web of Science ®Google Scholar
• Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128(4):504–507. doi:10.1182/blood-2016-03-707562
   PubMed Web of Science ®Google Scholar
• Bader P, Kreyenberg H, Henze GHR, et al. Prognostic value of Minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol. 2009;27(3):377–384. doi:10.1200/JCO.2008.17.6065
   PubMed Web of Science ®Google Scholar
• Sutton R, Shaw PJ, Venn NC, et al. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. Br J Haematol. 2015;168(3):395–404. doi:10.1111/bjh.13142
   PubMed Web of Science ®Google Scholar
• Logan AC, Vashi N, Faham M, et al. Immunoglobulin and t cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant. 2014;20(9):1307–1313. doi:10.1016/j.bbmt.2014.04.018
   PubMed Web of Science ®Google Scholar
• Spinelli O, Peruta B, Tosi M, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007;92(5):612–618. doi:10.3324/haematol.10965
   PubMed Web of Science ®Google Scholar
• Jabbour E, Short NJ, Jorgensen JL, et al. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017;123(2):294–302. doi:10.1002/cncr.30264
   PubMed Web of Science ®Google Scholar
• Dhédin N, Huynh A, Maury S, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125(16):2486–2496. doi:10.1182/blood-2014-09-599894
   PubMed Web of Science ®Google Scholar
• Friend BD, Bailey-Olson M, Melton A, et al. The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2020;67(2):e28079. doi:10.1002/pbc.28079
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell - Engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493–2498. doi:10.1200/JCO.2010.32.7270
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131(14):1522–1531. doi:10.1182/blood-2017-08-798322
   PubMed Web of Science ®Google Scholar
• Hilal T, Prasad V. Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission. Nat Rev Clin Oncol. 2018;15(12):727–728. doi:10.1038/s41571-018-0087-y
   PubMed Web of Science ®Google Scholar
• Goekbuget N, Stelljes M, Viardot A, et al. First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL). Blood. 2021;138(Supplement 1):362. doi:10.1182/BLOOD-2021-146306
   Google Scholar
• Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376(9):836–847. doi:10.1056/nejmoa1609783
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016;375(8):740–753. doi:10.1056/nejmoa1509277
   PubMed Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):449–459. doi:10.1056/nejmoa1709919
   PubMed Web of Science ®Google Scholar
• O’Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008;113(8):2097–2101. doi:10.1002/cncr.23819
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19(2):240–248. doi:10.1016/S1470-2045(18)30011-1
   PubMed Web of Science ®Google Scholar
• O’Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113(11):3186–3191. doi:10.1002/cncr.23919
   PubMed Web of Science ®Google Scholar
• Advani AS, Moseley A, O’Dwyer KM, et al. Results of SWOG 1318: a Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia. Blood. 2018;132(Supplement 1):33. doi:10.1182/blood-2018-99-111992
   Web of Science ®Google Scholar
• Short NJ, Kantarjian HM, Ravandi F, et al. Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: results from a Phase II Study. Blood. 2020;136(Supplement 1):9–11. doi:10.1182/BLOOD-2020-138565
   Web of Science ®Google Scholar
• Jabbour E, Short NJ, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018;5(12):e618–e627. doi:10.1016/S2352-3026(18)30176-5
   PubMed Web of Science ®Google Scholar
• Sasaki K, Jabbour EJ, Ravandi F, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2016;122(23):3650–3656. doi:10.1002/CNCR.30231
   PubMed Web of Science ®Google Scholar
• Giebel S, Czyz A, Ottmann O, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the acute leukemia working party of the. Cancer. 2016;122(19):2941–2951. doi:10.1002/cncr.30130
   PubMed Web of Science ®Google Scholar
• Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a Phase II, single-arm, multicenter study. J Clin Oncol. 2017;35(16):1795–1802. doi:10.1200/JCO.2016.69.3531
   PubMed Web of Science ®Google Scholar
• Foà R, Bassan R, Vitale A, et al. Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2020;383(17):1613–1623. doi:10.1056/NEJMOA2016272/SUPPL_FILE/NEJMOA2016272_DATA-SHARING.PDF
   PubMed Web of Science ®Google Scholar
• Short NJ, Kantarjian HM, Konopleva M, et al. Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: early results from a phase II study. Vaccine. 2021;39(15_suppl):7001. doi:10.1200/JCO.2021.39.15_SUPPL.7001
   PubMed Web of Science ®Google Scholar